GAIN THERAPEUTICS, INC Increase (Decrease) in Operating Capital
GAIN THERAPEUTICS, INC (GANX) reported Increase (Decrease) in Operating Capital of $471.64 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingCapital · last filed 2026-08-11
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for the quarter ending 2026-06-30 was $697.57K, a 37.44% increase year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for the quarter ending 2026-03-31 was -$225.93K.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for the quarter ending 2025-12-31 was $522.01K, a 15.94% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for the quarter ending 2025-09-30 was $135.75K, a 92.95% decline year-over-year.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for fiscal 2025 was $1.01M, a 6.84% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for fiscal 2024 was $1.08M.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for fiscal 2023 was -$442.23K.
- GAIN THERAPEUTICS, INC increase (decrease) in operating capital for fiscal 2022 was -$1.51M, a 559.35% decline from fiscal 2021.
| Period end | Increase (Decrease) in Operating Capital 3 month | Increase (Decrease) in Operating Capital 6 month | Increase (Decrease) in Operating Capital 9 month | Increase (Decrease) in Operating Capital 12 month |
|---|---|---|---|---|
| 2026-06-30 | $697.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $471.64K 10-Q · filed 2026-08-11 | $993.64K derived: sum of 3 quarters · filed 2026-08-11 | $1.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$225.93K 10-Q · filed 2026-05-11 | $296.08K derived: sum of 2 quarters · filed 2026-05-11 | $431.83K derived: sum of 3 quarters · filed 2026-05-11 | $939.36K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $522.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $657.76K derived: sum of 2 quarters · filed 2026-03-26 | $1.17M derived: sum of 3 quarters · filed 2026-08-11 | $1.01M 10-K · filed 2026-03-26 |
| 2025-09-30 | $135.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $643.28K derived: sum of 2 quarters · filed 2026-08-11 | $484.50K 10-Q · filed 2025-11-12 | $1.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $507.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $348.75K 10-Q · filed 2026-08-11 | $969.78K derived: sum of 3 quarters · filed 2026-08-11 | $2.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$158.78K 10-Q · filed 2026-05-11 | $462.25K derived: sum of 2 quarters · filed 2026-05-11 | $2.39M derived: sum of 3 quarters · filed 2026-05-11 | $1.34M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $621.03K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.55M derived: sum of 2 quarters · filed 2026-03-26 | $1.50M derived: sum of 3 quarters · filed 2026-03-26 | $1.08M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $876.16K derived: sum of 2 quarters · filed 2025-11-12 | $459.36K 10-Q · filed 2025-11-12 | $1.84M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.47M 10-Q · filed 2025-08-12 | -$86.76K derived: sum of 3 quarters · filed 2025-08-12 | -$81.58K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$416.81K 10-Q · filed 2025-05-14 | $962.56K derived: sum of 2 quarters · filed 2025-05-14 | $967.74K derived: sum of 3 quarters · filed 2025-05-14 | -$401.57K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.38M derived: sum of 2 quarters · filed 2025-03-27 | $15.24K derived: sum of 3 quarters · filed 2025-03-27 | -$442.23K 10-K · filed 2025-03-27 |
| 2023-09-30 | $5.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.36M derived: sum of 2 quarters · filed 2024-11-14 | -$1.82M 10-Q · filed 2024-11-14 | -$2.16M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.83M 10-Q · filed 2024-08-08 | -$2.16M derived: sum of 3 quarters · filed 2024-08-08 | -$3.09M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$457.47K 10-Q · filed 2024-05-14 | -$791.49K derived: sum of 2 quarters · filed 2024-05-14 | -$1.72M derived: sum of 3 quarters · filed 2024-05-14 | -$1.46M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$334.02K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$1.27M derived: sum of 2 quarters · filed 2024-03-26 | -$1.00M derived: sum of 3 quarters · filed 2024-03-26 | -$1.51M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$931.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$670.34K derived: sum of 2 quarters · filed 2023-11-14 | -$1.18M 10-Q · filed 2023-11-14 | $202.90K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $261.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$249.34K 10-Q · filed 2023-08-10 | $1.13M derived: sum of 3 quarters · filed 2023-08-10 | -$585.07K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$510.50K 10-Q · filed 2023-05-12 | $873.24K derived: sum of 2 quarters · filed 2023-05-12 | -$846.23K derived: sum of 3 quarters · filed 2023-05-12 | -$654.30K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$335.74K derived: sum of 2 quarters · filed 2023-03-23 | -$143.80K derived: sum of 3 quarters · filed 2023-03-23 | $329.78K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.53M derived: sum of 2 quarters · filed 2022-11-10 | -$1.05M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $191.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $665.52K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $473.59K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |